LEADER 03098nam 2200649 a 450 001 9910457137103321 005 20200520144314.0 010 $a1-283-01910-8 010 $a9786613019103 010 $a0-309-15890-7 035 $a(CKB)2550000000032026 035 $a(EBL)3378748 035 $a(SSID)ssj0000507437 035 $a(PQKBManifestationID)11344055 035 $a(PQKBTitleCode)TC0000507437 035 $a(PQKBWorkID)10562131 035 $a(PQKB)10436788 035 $a(MiAaPQ)EBC3378748 035 $a(Au-PeEL)EBL3378748 035 $a(CaPaEBR)ebr10454969 035 $a(CaONFJC)MIL301910 035 $a(OCoLC)923283190 035 $a(EXLCZ)992550000000032026 100 $a20110414d2011 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBuilding a national framework for the establishment of regulatory science for drug development$b[electronic resource] $eworkshop summary /$fInstitute of Medicine of the National Academies ; Yeonwoo Lebovitz, Rebecca A. English, and Anne B. Claiborne, rapporteurs 210 $aWashington, D.C. $cNational Academies Press$d2011 215 $a1 online resource (95 p.) 300 $a"Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy." 311 $a0-309-15889-3 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""Figures and Boxes""; ""Acronyms""; ""Preface""; ""1 Introduction""; ""2 Defining Regulatory Science""; ""3 The Urgent Need for Regulatory Science""; ""4 Barriers to Enhanced Regulatory Science""; ""5 Potential Models for Building a Regulatory Science Infrastructure""; ""6 Challenges in Engaging the Public Policy Community""; ""7 Envisioning Successful Regulatory Science at FDA""; ""8 Considering Next Steps""; ""References""; ""Appendix A: Agenda""; ""Appendix B: Participant Biographies"" 606 $aPharmaceutical policy$zUnited States$vCongresses 606 $aDrug development$xGovernment policy$zUnited States$vCongresses 606 $aPharmaceutical industry$xGovernment policy$zUnited States$vCongresses 608 $aElectronic books. 615 0$aPharmaceutical policy 615 0$aDrug development$xGovernment policy 615 0$aPharmaceutical industry$xGovernment policy 676 $a615.1 701 $aLebovitz$b Yeonwoo$0936149 701 $aEnglish$b Rebecca A$0897032 701 $aClaiborne$b Anne B$0897033 712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation. 712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy. 712 12$aBuilding a National Framework for the Establishment of Regulatory Science for Drug Development$f(2010 :$eWashington, D.C.) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910457137103321 996 $aBuilding a national framework for the establishment of regulatory science for drug development$92125496 997 $aUNINA LEADER 01862nam0 2200373 i 450 001 USM1369296 005 20251003044435.0 010 $a8814110824 020 $aIT$b2005-399 100 $a20130827d2004 ||||0itac50 ba 101 | $aita 102 $ait 181 1$6z01$ai $bxxxe 182 1$6z01$an 200 1 $aAutonomia contrattuale e garanzie nella vendita di beni di consumo$fCristiano Iurilli 210 $aMilano$cA. Giuffrè$d2004 215 $aX, 248 p.$d24 cm. 225 | $aPubblicazioni della Facoltà di giurisprudenza$fII Università degli studi di Roma$g[poi] Università degli studi di Roma Tor Vergata.$i$v17 410 0$1001RMG0027253$12001 $aPubblicazioni della Facoltà di giurisprudenza$fII Università degli studi di Roma$g[poi] Università degli studi di Roma Tor Vergata.$i$v17$171201$aUniversità degli studi di Roma Tor Vergata$b : Facoltà di giurisprudenza$3CFIV094304 606 $aContratti del consumatore$2FIR$3CFIC097196$9I 606 $aConsumatori$xTutela$xLegislazione$xItalia$2FIR$3CFIC016883$9E 676 $a346$9Diritto privato$v12 676 $a346.4502$9CONTRATTI E RAPPRESENTANZA. ITALIA$v21 696 $aTutela giuridica 699 $aTutela$zTutela giuridica 700 1$aIurilli$b, Cristiano$3RMGV010756$4070$0310281 801 3$aIT$bIT-000000$c20130827 850 $aIT-BN0095 901 $bNAP 01$cD $n$ 912 $aUSM1369296 950 0$aBiblioteca Centralizzata di Ateneo$c1 v.$d 01D (C) 00 1930$e 01C 0080019305 VMA 1 v.$fY $h20121024$i20121024$c1 v.$d 01D (C) 23 051$e 01C 0800230515 VMA 1 v.$fY $h20120913$i20120913 977 $a 01 996 $aAutonomia contrattuale e garanzie nella vendita di beni di consumo$969835 997 $aUNISANNIO